title: Long-term consequences with regard to clinical outcome and cost-effectiveness of episodic treatment with omeprazole or ranitidine for healing of duodenal ulcer.
abstract: The clinical outcome and cost-effectiveness of episodic treatment of duodenal ulcer with omeprazole and ranitidine were evaluated over a 5-year period. The analysis was based on data from published clinical trials comparing healing rates obtained with omeprazole and with ranitidine, as well as on data from the literature on ulcer recurrence and other clinical events. Patients with an active duodenal ulcer were treated until healed or for a maximum of 24 weeks. Maintenance therapy was instituted in patients with ulcers that were very slow to heal and in patients with frequent relapses after cessation of treatment. Patients who experienced frequent relapses while receiving maintenance therapy, and those whose ulcer had not healed after 24 weeks of continuous treatment, were defined as candidates for surgery. A statistical model was set up and a random number generator used to generate a sequence of clinical events, month by month, over a 5-year period for each patient in a large cohort. Episodic treatment with omeprazole was shown to be more effective in avoiding maintenance treatment and surgery when compared with episodic treatment with ranitidine. Patients who received episodic treatment with omeprazole also spent more time in remission from disease. Using current Swedish cost data, it was found that episodic treatment with omeprazole was more cost-effective than episodic treatment with ranitidine.
authors.affiliation: Dept. of Medicine, Astra Hässle AB, Mölndal, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Walan
authors.forename: S
authors.initials: S
authors.lastname: Eriksson
mesh_terms: D003362:Cost-Benefit Analysis; D016527:Drug Costs / Q000706:statistics & numerical data; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D009853:Omeprazole / Q000008:administration & dosage / Q000191:economics*; D011336:Probability; D011379:Prognosis; D011899:Ranitidine / Q000008:administration & dosage / Q000191:economics*; D012537:Scandinavian and Nordic Countries; D016896:Treatment Outcome
chemical_list: D011899:Ranitidine; D009853:Omeprazole